Figures released by Nicholas Hall’s sales database DB6 show that in the 12 months to end-September 2019 (MAT Q3 2019) the global CHC market increased by 3.7%, a slight improvement on its MAT Q2 2019 performance (+3.6%). Global CHC sales now total US$139.5bn.
USA maintained its growth rate (+2.7%) with slight improvements in CCA and analgesics being offset by slower performances in other major categories. Canada continued to perform poorly with sales up by just 1.9%, and the country has fallen to No. 12 position in the global rankings, behind Poland, which saw growth accelerate to 8.7%. Also contributing to an improved performance in Europe (+2.6%) were strong upturns for key markets Germany, UK and Italy, though Russia, France and Switzerland continued to decline.
Asia-Pacific remained weak (+4.0%) with China and India both slowing upon their MAT Q2 performances and all other leading Asian markets growing by under 3%. Japan reported consistent growth of 0.9%, while Australia (+1.8%) and South Korea (+2.2%) recorded modest upturns in Q3. Latin America (+9.1%) maintained its high growth trend with both Brazil and Mexico advancing by high single digits. Turkey also posted a strong performance (+18.0%), primarily driven by price inflation.
Nicholas Hall’s Christmas Card: The global CHC market will struggle to reach 4% growth in 2019, at least in the Retail sector. By next March we will have 2019 data for all three channels, including Direct and Internet, and it will be interesting to see whether the industry matches the 5% growth achieved in 2018. Looking at the market very simply, there are three short-term drivers: a strong cold & flu season, and it does seem as though we will be sneezing a lot more in the months ahead; Rx-to-Switch, but 2019 is the second year of no significant switches, although Sanofi’s statement about Cialis and Tamiflu is welcome for the future; and the Emerging Markets, all growing significantly less than in the past as proved by our Q3 data.
Explore the Emerging Markets, Industry Consolidation and many other pressing issues in Nicholas Hall’s New Paradigms for CHC 2019: Over the Horizon! Nicholas also unveils his 15 ”Infinity Zones” that are crucial to the future growth of the industry in this essential report. You can upgrade your purchase to include a customised in-house presentation or webinar with Nicholas for an additional GB£10,000. For more information, or to order your copy, currently available with a 15% discount until 31 December only, please contact melissa.lee@NicholasHall.com.
Nicholas Hall Company Blog 